Pembrolizumab in First-line Gastric Cancer: Win, Lose, or Draw?
JAMA Oncol
.
2020 Oct 1;6(10):1539-1541.
doi: 10.1001/jamaoncol.2020.2436.
Authors
Elizabeth C Smyth
1
,
Markus Moehler
2
Affiliations
1
Department of Oncology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, Cambridgeshire, United Kingdom.
2
Department of Internal Medicine, University Medical Centre of the Johannes Gutenberg University, Mainz, Germany.
PMID:
32880639
DOI:
10.1001/jamaoncol.2020.2436
No abstract available
Publication types
Editorial
Comment
MeSH terms
Adenocarcinoma*
Antibodies, Monoclonal, Humanized
Humans
Stomach Neoplasms* / drug therapy
Substances
Antibodies, Monoclonal, Humanized
pembrolizumab